Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University Hospital Tuebingen)
- Development stage
- Preclinical
- Lead developer
- University Hospital Tuebingen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Intranasal
01
Overview
Fecal microbiota transplantation (FMT) is a biologic therapy investigated by the University Hospital Tuebingen in the TOCSIN clinical trial (NCT01942447) for the treatment of recurrent or refractory Clostridium difficile infection (CDI). [9] The procedure involves the administration of fecal matter from a healthy donor into the gastrointestinal tract of a patient. [2, 4] This process aims to restore a healthy gut microbiome, thereby re-establishing colonization resistance against the pathogenic C. difficile bacteria and breaking the cycle of recurrent infection. [2, 4, 14] The 'active ingredient' is the complex community of microorganisms, including bacteria and their metabolites, present in the donor stool. [2]
- Other names
- FMTfecal microbiota transplantfecal bacteriotherapy
Beyond the preview
Go deeper on fecal microbiota transplantation (University Hospital Tuebingen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University Hospital Tuebingen).